11.02.26 -- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale

Guidance on designing viral clearance studies using regulatory-aligned, risk‑based strategies, optimized assays, and real case examples for safe, efficient biologics development.

Japan is emerging as a credible cell and gene therapy hub as regulation, manufacturing, and capital advance, despite gaps in funding, talent, risk culture, and language.

Discover how the evolution of T7 polymerase is optimizing in vitro transcription for RNA therapeutics. Learn to balance performance, cost, and supply to make smart choices for your xRNA manufacturing.

This comprehensive exploration aims to shed light on the critical aspects of expediting curative therapies, with a focus on the strategic role that CDMOs can play in this transformative journey.

Uncover how integrated custom media solutions can accelerate the path to manufacturing success, supporting both clients with established formulations and those seeking new designs.

Late-stage viral vector programs leave almost no margin for error. Regulatory, operational, and market pressures shape the path to commercial launch, and the choice of manufacturing partner carries real weight.

Engineered AAV capsids offer improved targeting and efficiency but introduce manufacturing, analytical, immunogenicity, and regulatory complexities requiring early, integrated development strategies.